Latus
Latest round
- Series A
Last raised
- May 2026
Total raised
- $77M
Investors
- 10
About Latus
In May 2026, Latus Bio, Inc. Latus Bio, Inc. specializes in utilizing adeno-associated virus (AAV) vectors to improve the treatment of central nervous system (CNS) disorders. The company’s technology is designed to accurately deliver therapeutic genes to specific tissues, reducing the risks of immunogenicity and toxicity commonly associated with high-dose administrations. Its program target CNS diseases such as Huntington's Disease (HD) and CLN2, provides patients with one-time gene therapies that offer meaningful reductions in toxicity and improved quality of life.
Who invested in Latus
10 investors across 2 rounds
See all investors in Latus
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Latus
Who invested in Latus?
Latus has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Latus raised?
Latus has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Latus last raise money?
Latus's most recent round on record is a Series A, in May 2026.
What does Latus do?
Latus is a biotechnology company.
Where is Latus headquartered?
Latus is headquartered in Philadelphia, US.
Which VCs invest in companies like Latus?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Latus's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Latus? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.